Treatment consisted of 4-6 cycles of dose-dense intensive chemotherapy incorporating hyperfractionated ...

The trial recruited children and young adults with Philadelphia-negative ALL and lymphoblastic lymphoma (LBL) diagnosed in the United Kingdom and Ireland except those younger than 1 year or with ...

CAR-T therapy costs about Rs 50 lakh in India including hospital fees, much less than the Rs 3-4 crore or more (before ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

Indolent T/B-lymphoblastic proliferation ... requiring careful immunohistochemical differentiation from leukemia/lymphoma. Castleman disease encompasses a spectrum of histologic and clinical ...

Allogene Therapeutics, Inc.’s ALLO share price has surged by 6.64%, which has investors questioning if this is right time to ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric ...

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL ... to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is ...

clonoSEQ testing for patients with MCL is currently available for clinical use as a laboratory-developed test performed at Adaptive's CLIA-certified lab in Seattle. clonoSEQ testing in MCL has also ...